Merck offered $200 a share for Prometheus, well above its $114 close last week. (TOM MIHALEK/AFP via Getty Images) Merck & Co. is paying $10.8 billion to buy Prometheus Biosciences for its late-phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results